- About Circio
- CEO Statement
- Pipeline
- Management Team
- Board of Directors
- Careers
- The Norwegian Transparency Act

- Circio AB
- circVec platform

Clinical programs

- KRAS program
- Publications

- Press releases
- Events
- Reports
- Presentations
- Prospectus
- Debt
- Share information
- Contact

- Press releases
- Events
- Subscribe
- Contact

About
circRNA
- Circio AB
- circVec platform
Clinical programs
- KRAS program
- Publications
Partnering
- Partnering
Investors
Media
Contacts
- Offices
- Investors & Media

Search for:

Extraordinary General Meeting November 2017

November 30, 2017

01:00 PM CET
Oslo, Norway

Documents

Notice of EGM
Protocol

IR contact

Dr Erik Digman Wiklund

CEO

erik.wiklund@circio.com

+47 41 33 35 36

Dr Lubor Gaal

Chief Financial Officer

lubor.gaal@circio.com

(+34) 683 343 811

Half-year Report – Q2

Circio announced its first half year 2023 results on Thursday 24 August 2023.

Webcast: 10:00 a.m. CET the same day

Report
Presentation
Webcast

Read the report

Subscribe

Press releases

Financial reports

Language

English

Norwegian

Read more about our Protection of your personal data.

Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

About
circRNA
Clinical programs
Partnering
Investors
Media
Contacts

CONTACT

Circio Holding ASA
Email: contact@circio.com

Cookies
Privacy policy

STAY CONNECTED